PhRMA keeps eye on Indian compulsory licensing activity
This article was originally published in Scrip
Executive Summary
Despite its seemingly measured reaction to the latest compulsory licensing application for AstraZeneca's saxagliptin in India, PhRMA (Pharmaceutical Research and Manufacturers of America) appears to be keeping a sharp eye on the developments in the area.